CAMP4 Therapeutics announces up to $100M private placement and board changes

Camp4 Therapeutics Corp

Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.
Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.
Directors James Boylan, Ravi Thadhani, and Paula Ragan resigned; Doug Williams appointed Board Chair.
Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025.
Financing led by Coastlands Capital with Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures and others.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Camp4 Therapeutics Corp issued 26,681,053 shares of common stock to certain accredited investors for $1.53 per Share.

Security: common stock
Shares: 26,681,053 shares
Purchaser: certain accredited investors
Consideration: $1.53 per Share

Exact text from the filing

At the Initial Closing, the Company has agreed to issue and sell 26,681,053 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $1.53 per Share (the “ Share Price ”)

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Camp4 Therapeutics Corp issued pre-funded warrants to purchase 6,003,758 shares of Common Stock of warrant to certain accredited investors for $1.5299 per pre-funded warrant.

Security: warrant
Shares: pre-funded warrants to purchase 6,003,758 shares of Common Stock
Purchaser: certain accredited investors
Consideration: $1.5299 per pre-funded warrant

Exact text from the filing

in lieu of Common Stock to certain Investors, pre-funded warrants to purchase 6,003,758 shares of Common Stock (the “ Warrant Shares ” and, together with the Shares, the “ Securities ”) at an offering price of $1.5299 per pre-funded warrant (the “ Pre-Funded Warrant Price ”)

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Camp4 Therapeutics Corp issued an additional 36,361 Shares of common stock to certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon for a purchase price of $1.65 per share.

Security: common stock
Shares: an additional 36,361 Shares
Purchaser: certain members of management including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young and Leonard Zon
Consideration: a purchase price of $1.65 per share

Exact text from the filing

the Company will issue and sell to certain members of management, including the Company’s CEO Josh Mandel-Brehm, the Company’s CFO Kelly Gold, the Company’s CMO Yuri Maricich, and the Company’s co-founders Richard Young, who also serves as a director on the Company’s Board of Directors (the “ Board ”) and Leonard Zon, who serves as a Board observer, an additional 36,361 Shares at a purchase price of $1.65 per share

View on SEC.gov

Browse all equity issuances →

Camp4 Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001736730-25-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.